Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 13/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CFTR | P13569 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476781 | 0.90 | BAZ2B (0.64) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL3477408 | 0.90 | BAZ2B (0.64) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL29171353 | 0.84 | BAZ2B (0.79) | BAZ2BMAPTALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL28475633 | 0.84 | BAZ2B (0.79) | BAZ2BMAPTMAPK1LMNAPABPC1 | |
| SCHEMBL3424575 | 0.84 | BAZ2B (0.81) | BAZ2BMAPTUSP2ALDH1A1LMNA | |
| SCHEMBL764099 | 0.83 | LMNA (0.79) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL409534 | 0.82 | BAZ2B (0.71) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL1004951 | 0.82 | BAZ2B (0.55) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL27246699 | 0.82 | BAZ2B (0.61) | BAZ2BMAPTUSP2ALDH1A1MAPK1 | |
| SCHEMBL29171356 | 0.81 | BAZ2B (0.82) | BAZ2BUSP2LMNAPABPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-9296743-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2925129-A1 | PRO-NEUROGENIC COMPOUNDS | Board of Regents of the University of Texas System (US) | 2015-10-07 | — | — | EP | disclosed |
| EP-2476680-B1 | (1-Azinone)-Substituted Pyridoindoles | ALBANY MOLECULAR RES INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716308-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| WO-2014031125-A1 | PRO-NEUROGENIC COMPOUNDS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-27 | — | — | WO | disclosed |
| EP-2476680-A1 | (1-Azinone)-Substituted Pyridoindoles | Albany Molecular Research, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331339-A9 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | BAZ2B 370/4885MAPT 4505/4885USP2 4706/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | BAZ2B 401/4885MAPT 4451/4885USP2 4741/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | BAZ2B 370/4885MAPT 4505/4885USP2 4706/4885 |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | BAZ2B 401/4885MAPT 4451/4885USP2 4741/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | BAZ2B 401/4885MAPT 4451/4885USP2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.